Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Key Inclusion Criteria:

• Participants legally competent to sign and give informed consent and, if appropriate,assent as required by local laws.
• Males and females ages 9 years and older at the time of consent.
• Clinical diagnosis of seborrheic dermatitis of at least 3 months duration at Screeningas determined by the Investigator. Stable disease for the past 4 weeks.
• Seborrheic dermatitis up to 20% BSA involvement. Involvement may be of the scalpand/or face and/or trunk and/or intertriginous areas.
• An Investigator Global Assessment (IGA) disease severity of at least Moderate ('3') atBaseline.
• Overall Assessment of Erythema and Overall Assessment of Scaling scores of at leastModerate ('2') at Baseline.
• Females of childbearing potential (FOCBP) must have a negative serum pregnancy test atScreening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).
• Females of non-childbearing potential must either be post-menopausal with spontaneousamenorrhea for at least 12 months or have undergone surgical sterilization.
• Subjects in good health as judged by the Investigator.
• Subjects are considered reliable and capable of adhering to the Protocol and visitschedule according to the Investigator judgment.

Key Exclusion Criteria:

• Subjects who cannot discontinue treatment with therapies for the treatment ofseborrheic dermatitis prior to the Baseline visit and during the study.
• Planned excessive exposure of treated area(s) to either natural or artificialsunlight, tanning bed or other LED.
• Previous treatment with ARQ-154 or ARQ-151.
• Subjects with any serious medical condition or clinically significant abnormality thatwould prevent study participation or place the subject at significant risk, as judgedby the Investigator.
• Females who are pregnant, wishing to become pregnant during the study, or arebreast-feeding.
• Subjects with a history of chronic alcohol or drug abuse within 6 months prior toScreening.
• Subjects, parent(s)/legal guardian(s) who are unable to communicate, read, orunderstand the local language(s).
• Subjects who are family members of the clinical study site, clinical study staff, orsponsor, or family members living in the same house of enrolled subjects.